Dr. Heller and his team are partnering with COUR Pharmaceuticals to study CNP-201, a biodegradable nanoparticle encapsulating peanut protein. It has the potential to treat patients with peanut allergy by reducing the need for strict peanut avoidance and reducing the potentially fatal health risks associated with peanut allergy.
By harnessing the immune system’s built-in learning and regulatory pathways, COUR nanoparticle technology can reprogram the immune system providing clinicians with a breakthrough approach to treating allergy.
Dr. Heller is especially excited about the project, stating “Current treatments focus on suppressing the immune system, but we are studying way we can essentially reprogram the T Cells, and avoid such suppression.”
The study will recruit participants ages 16-65, patients may be reimbursed for their time and travel.
Long Beach Clinical Trials has been conducting research in Long Beach since 2014.
If you are interested in learning more about this study and the qualifications to participate please call 562-436-4761 or visit www.longbeachclinicaltrials.com